Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
about
Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial.In Vitro Activity of Rifampicin Combined with Daptomycin or Tigecycline on Staphylococcus haemolyticus BiofilmsHigh-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.Daptomycin-Nonsusceptible Staphylococcus aureus: The Role of Combination Therapy with Daptomycin and Gentamicin.In vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus.Daptomycin: pharmacology and clinical use.Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.Should daptomycin-rifampin combinations for MSSA/MRSA isolates be avoided because of antagonism?Management of acute hematogenous osteomyelitis in children.Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin.New in vitro and in vivo models to evaluate antibiotic efficacy in Staphylococcus aureus prosthetic vascular graft infection.Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections.[Infective endocarditis : Update on prophylaxis, diagnosis, and treatment].2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the EurUnpredictable effects of rifampin as an adjunctive agent in elimination of rifampin-susceptible and -resistant Staphylococcus aureus strains grown in biofilms.Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.Experimental study of the efficacy of daptomycin for the treatment of cephalosporin-resistant pneumococcal meningitis.Comparative efficacies of cloxacillin-daptomycin and the standard cloxacillin-rifampin therapies against an experimental foreign-body infection by methicillin-susceptible Staphylococcus aureusCalming the "perfect storm" in methicillin-resistant Staphylococcus aureus bacteremia: a call for a more balanced discussion.Daptomycin.
P2860
Q34045273-D7A3FEE9-6BC0-4842-A723-C700327B8736Q34157657-3A6B3762-555B-4E43-8DD1-C0FA96A09502Q34478074-2489D855-01D6-4766-A449-AF5D21C2206CQ35179800-189F232A-7443-4ECA-8F28-855771F6615CQ35610157-8E7AD3B2-0FA9-48BA-9453-525316B5192AQ36171512-218AB70A-C272-49EF-A3BE-56953D77AD08Q36401160-E5FADC31-F412-4E8B-9232-AF83F65B5C13Q37263546-0155CC46-A0BA-4885-A8DE-78276A34F879Q37693931-307254F7-CAC7-43AC-8418-77AF3D0CB84AQ38577676-05A99F5E-D12C-406E-84DB-B2F1CD0FCD42Q38926289-263623D4-E06D-45F2-80BC-0257532D5087Q39488590-DE6E424F-F6D0-4C2F-A068-BE9A28EDB291Q39564607-09E85D04-09AC-459A-959A-1149D6A51130Q40003948-1546DAA4-76D5-4614-A0D1-FBC83FAEE49CQ40018152-BED4E027-27B8-4AA9-BF3A-9A806817A0F0Q40631566-3906CF8E-6BAD-4FCD-879A-E1FBA5009971Q40679827-5BB60ED5-C6DF-47A2-BECB-DED3786B01A2Q41026009-3799A90E-9F80-443F-8AA9-6CBE9E8D4681Q41869974-282225EA-D809-4AFF-A6B9-4A00A8C07A03Q42036509-984415EE-16BE-4370-A08C-01DBBFB5FEE8Q42209068-68EFD48F-D06C-4B92-88E5-65964BDEA0E1Q42209248-451DE0D8-7F1A-49A0-90A8-73BF8C9F4BB8Q45230350-20D55CAD-3DA3-42BE-9901-5D0D50595110Q47616115-D0D4B581-0C22-45A3-84B5-93703C645210
P2860
Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Addition of gentamicin or rifa ...... sistant Staphylococcus aureus.
@en
Addition of gentamicin or rifa ...... sistant Staphylococcus aureus.
@nl
type
label
Addition of gentamicin or rifa ...... sistant Staphylococcus aureus.
@en
Addition of gentamicin or rifa ...... sistant Staphylococcus aureus.
@nl
prefLabel
Addition of gentamicin or rifa ...... sistant Staphylococcus aureus.
@en
Addition of gentamicin or rifa ...... sistant Staphylococcus aureus.
@nl
P2093
P2860
P356
P1476
Addition of gentamicin or rifa ...... sistant Staphylococcus aureus.
@en
P2093
C A Mestres
C García-de-la-Mària
Hospital Clinic Experimental Endocarditis Study Group
J M Gatell
P2860
P304
P356
10.1128/AAC.00051-09
P407
P577
2009-07-20T00:00:00Z